Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Key PointsViking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.